Using Phenazopyridine for In-office Cystoscopy

Boston Urogynecology Associates

Status: Unknown

Conditions: Phenazopyridine; Cystoscopy

Treatments: Drug: Phenazopyridine

Study type: Interventional

Funder types: Other

Identifiers

NCT02715648

003-2016

Details and patient eligibility

About

The investigators propose to conduct a randomized controlled trial to evaluate whether administration of phenazopyridine prior to the procedure decreases office cystoscopy time. Women undergoing in-office cystoscopy at Boston Urogynecology will be recruited.

Full description

All potentially eligible participants will have had a complete history, physical examination, urinalysis and urine culture for clinical purposes. After eligibility is confirmed and written, informed consent is obtained, participants will be randomized to one of the two study arms. Participants randomized to phenazopyridine arm will receive 200 mg by mouth approximately 60 minutes prior to the scheduled cystoscopy. During the cystoscopy, at various time points, the time will be recorded.The color of the efflux will also be documented.

Enrollment: 94 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients undergoing in-office diagnostic cystoscopy at Boston Urogynecology Associates

Exclusion criteria

• Women who have taken vitamin B the day of the cystoscopy
• Cystoscopy with concurrent treatments such as botulinum toxin or periurethral bulking injections
• Allergy to phenazopyridine

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

94 participants in 2 patient groups

No Phenazopyridine before cystoscopy

No Intervention group

Description:

This group will not receive phenazopyridine prior to cystoscopy

Phenazopyridine before cystoscopy

Experimental group

Description:

This group will receive 200mg of phenazopyridine prior to cystoscopy

Treatment:

Drug: Phenazopyridine